Kayne Anderson Rudnick Investment Management
PHAT icon

Kayne Anderson Rudnick Investment Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39
Closed -$1K – 660
2022
Q1 		$1K Buy
+39
New +$630 ﹤0.01% 640

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's PHAT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2022, closing a stake of 39 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in PHAT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 94 funds tracked by Wall St. Rank hold PHAT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Phathom Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 39 Phathom Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Phathom Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Phathom Pharmaceuticals position peaked at $1K in Q1 2022.
  • 94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.